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ABSTRACT 
 
The uterus is a major hormone-responsive reproductive organ in primates. Hormones 
promote their effect via different pathways. Receptors involved in steroid hormone, thyroid 
hormone and insulin signaling have been found in the endometrium. Several lines of evidence 
suggest that endocrine and metabolic disturbances may affect the endometrium adversely, 
leading to abnormalities and reproductive failure. This has stimulated research on factors and 
potential mechanisms that are related to endometrial dysfunction. The overall aim of this 
project was to increase the understanding of hormone receptor regulation of the primate 
uterus, and in particular to investigate the effects of different hormone treatments and lifestyle 
intervention on endometrial receptor expression. 
In paper I and II, 88 ovariectomized cynomolgus macaques were treated with conjugated 
equine estrogens (CEE), a combination of CEE + medroxyprogesterone acetate or tibolone 
(TIB), a compound with estrogenic, progestogenic and androgenic activity. At the end of the 
treatment period uterine tissues were collected and the presence and localization of receptors 
for steroid hormone and thyroid hormone signaling were investigated.  
In contrast to conventional hormone treatment, TIB treatment did not decrease the 
immunostaining of estrogen receptors in the endometrium of macaque uterus. However, 
androgen receptor expression in endometrial stroma in this group was higher as compared to 
controls, which could be one mechanism to explain the endometrial atrophy and beneficial 
bleeding profile that is associated with TIB treatment. 
Immunostaining of thyrotropin-releasing hormone (TRH) receptor, thyroid-stimulating 
hormone (TSH) receptor and thyroid hormone receptors was detected in all compartments of 
macaque uterus. Their expression was affected in a specific way by long-term sex hormone 
treatment. Thus, TRH, TSH and thyroid hormones may have direct effects on the 
endometrium and thereby influence its function. 
In paper III and IV, 20 overweight/obese women with polycystic ovary syndrome (OB-
PCOS) were recruited to a three months lifestyle intervention, aiming at weight reduction. 
Endometrial biopsies were collected at mid-proliferative and mid-secretory phases of the 
menstrual cycle. The endometrial expression of receptors involved in insulin and estrogen 
signaling was evaluated. 
Gene and protein expression of molecules involved in insulin signaling was up-regulated 
following lifestyle intervention, indicating improvement of glucose homeostasis and thereby 
endometrial functioning in these women. Moreover, lifestyle intervention influenced estrogen 
receptor expression towards normalization in the follicular phase of the menstrual cycle. In 
six OB-PCOS women ovulation was confirmed. Despite restored ovulation, endometrial 
expression of the proliferation marker Ki67 was higher in the secretory phase of OB-PCOS 
women as compared to controls. The elevated endometrial expression of the non-genomic 
estrogen receptor, G-protein coupled estrogen receptor-1, may be proposed as one 
mechanism behind the high proliferation activity in PCOS women. 
 
Key words: endometrium, hormone treatment, polycystic ovary syndrome, lifestyle 
intervention 
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1 INTRODUCTION 
 
The uterus is the major hormone-responsive reproductive organ in primates. The first 
knowledge about the uterus is coming from Egyptian papyrus texts. It took a long time before 
the anatomy of the uterus was accurately described by Soranus of Ephesus (98-138 A.D). The 
uterus is a flattened, pear-shaped organ. It is located in the pelvis and it is within the uterus 
that the full fetal development takes place during gestation. The uterus is built up of three 
layers. The outer thin layer is known as serosa. The middle layer of the uterus is represented 
by a thick smooth muscle wall, the myometrium. The uterus expands during pregnancy, 
providing protection for the fetus, and later during parturition the myometrium serves as a 
mechanism for fetal expulsion. The inner lining of the uterus is called endometrium and can 
be considered as one of the most complex tissues in the body because of the cyclical changes 
in response to sex steroid hormones produced by the ovaries (Figure 1).  
 
              
Figure 1. Female reproductive organs. 
 
 
1.1 THE MENSTRUAL CYCLE  
The normal menstrual cycle in women could be described depending on the organ of interest. 
The ovarian cycle consists of follicular, ovulatory and luteal phases while the endometrial 
changes are denoted as proliferative phase, secretory phase and menstruation (Figure 2). 
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Figure 2. The menstrual cycle (adopted from Wheater’s Functional Histology, 5th ed. Elsevier 
Limited, 2006)     
 
 
1.1.1 Ovarian cycle 
1.1.1.1 The follicular phase 
The first day of the menstruation marks the beginning of the new menstrual cycle. During the 
follicular phase, a cohort of ovarian follicles is recruited and starts to grow under the 
stimulation of follicular stimulating hormone (FSH) from the pituitary. Circulating levels of 
sex steroid hormones are low during the first days of the follicular phase but growing follicles 
start to produce estradiol. The estradiol concentration in the blood increases by the mid-
follicular phase and reaches its maximum on the day before ovulation. Usually a single 
follicle will be selected to become fully mature and ready to rupture, releasing the ovum that 
is ready for fertilization at the time of ovulation. 
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1.1.1.2 The ovulatory phase 
The rise in estradiol concentration stimulates the secretion of luteinizing hormone (LH) but 
inhibits FSH secretion from the pituitary. The blood concentration of LH peaks around mid-
cycle, the so called LH surge, and induces ovulation about 12 hours later. Androgen 
production at ovulation enhances atresia of the smaller follicles and stimulates libido. After 
the LH surge, estradiol levels decrease. 
1.1.1.3 The luteal phase  
After ovulation, the empty follicle is transformed into another structure, called the corpus 
luteum. Corpus luteum is producing both estrogen and progesterone. Levels of estradiol and 
progesterone increase after ovulation, peak in the mid-luteal phase and remain high during 
the lifespan of the corpus luteum. In the absence of fertilization, corpus luteum degeneration 
takes place and the production of sex steroid hormones decline. Sex steroid hormone 
withdrawal leads to endometrial breakdown and menstruation. 
1.1.2 Endometrial changes 
The human endometrium consists of two layers: the transient stratum functionalis (upper 
two-thirds) and the permanent stratum basalis (lower one third). The stratum functionalis is 
built up of a superficial zone, the stratum compactum and an intermediate zone, the stratum 
spongiosum. Both of them undergo degeneration and breakdown every month of a normal 
menstrual cycle. The stratum basalis does not respond to sex steroid hormone fluctuations; 
instead, it is the source of endometrial regeneration after each menstruation (Figure 3). 
         
Figure 3. Endometrial morphology (adopted from Pearson Education, Inc., publishing as Benjamin 
Cummings) 
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The functional layer consists of different cell types such as luminal epithelium, glandular 
epithelium and stromal cells (Figure 3). Epithelial and stromal compartments of the 
endometrium are changing in a dynamic fashion during each menstrual cycle in order to 
create an appropriate environment for implantation. The different phases of the endometrium 
are regulated by cyclic production of sex steroid hormones by the ovaries (Speroff and Fritz, 
2005). 
1.1.2.1 The proliferative phase 
During the proliferative phase, the endometrium is growing and proliferating under the rising 
secretion of estradiol from the ovaries. The endometrium is growing from approximately 2 
mm after menses to 10-12 mm in the periovulatory phase. Endometrial glands are becoming 
coiled and more closely packed and mitotic figures can be seen in glandular epithelium and 
stroma (Young et al., 2006).  
1.1.2.2 The secretory phase 
During the secretory phase, after ovulation, progesterone counteracts estradiol stimulation 
and the endometrium undergoes further transformation, known as cellular differentiation. At 
this stage the glands are containing glycogen vacuoles, while mitotic figures are not seen 
anymore. Secretory activity of the glands reaches its maximum around postovulatory day 6 to 
7 in preparation for implantation. At the same time, the stroma is beginning to show signs of 
edema which is continuously progressing until the late secretory phase (Young et al., 2006). 
Two days before menstruation, a massive leukocyte infiltration of the endometrium takes 
place, indicating its collapse. Regression of corpus luteum and subsequent decrease in sex 
steroid hormone production leads to the breakdown and shedding of stratum functionalis. 
1.1.2.3 Menstruation 
In the absence of fertilization and implantation, corpus luteum regression takes place and 
estradiol and progesterone levels decrease. The sex steroid hormones withdrawal leads to a 
profound vascular spasm of the spiral arteries, causing endometrial ischemia as well as a 
breakdown of lysosomes and a release of proteolytic enzymes. All these events are promoting 
endometrial destruction and shedding. Simultaneously, myometrial contractions increase and 
serve to physically discharge destroyed endometrium from the uterus.  
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1.2 ENDOMETRIUM 
1.2.1 Sex hormone receptors in the endometrium 
Sex steroid hormones promote their effect on the endometrium via genomic activation by 
binding to nuclear receptors (functional effect within hours) or more rapid non-genomic 
mechanisms via membrane-bound receptors (functional effect within minutes) (Figure 4). 
Classical genomic activation includes the presence of intracellular receptors. After simple 
diffusion through the cell membrane, sex steroid hormones bind to the respective steroid 
hormone receptor (SHR) and the hormone receptor complex that is formed interacts with a 
hormone response element (HRE) on the DNA which results in synthesis of messenger RNA 
(mRNA), its transportation to the ribosomes and protein synthesis. Many hormone responsive 
genes lack the HRE and interact with SHR via transcriptional factors, e.g. the specificity 
protein 1 (SP1) and activator protein 1 (AP-1). In addition to ligand dependent-pathways, 
ligand-independent pathways, as a response to signaling via growth factor receptors (so called 
cross-talk), have been described. Non-genomic activation involves membrane bound 
receptors, such as G protein coupled receptors, which are represented by a polypeptide chain 
that spans across the membrane. Interaction between receptor and hormone leads to the 
activation of second messengers. 
               
Figure 4. Mechanisms of steroid hormone action. Classical (1) and HRE (hormone response element) 
–independent (2) pathways mediate the genomic action via nuclear steroid hormone receptors (SHR). 
The hormone-receptor (HR) complex either binds DNA via the hormone response element (HRE) or 
via transcriptional factors, e.g. the specificity protein 1 (SP1) and activator protein 1 (AP-1). 
Activation of the HRE results in transcription and protein synthesis. Some estrogen receptor-mediated 
transcription can take place in the absence of a ligand (ligand independent pathway) (3) when 
receptors are activated by phosphorylation in response to signaling via growth factor receptors (s.c. 
cross-talk). By the non-genomic pathway (4), a rapid hormone action is mediated via binding to 
membrane-bound receptors and inducing a subsequent signaling cascade.  
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Steroid hormone receptors share a common structure with the thyroid hormone receptors. 
They all belong to the steroid/thyroid hormone super family of nuclear receptors (Figure 5).  
                        
Figure 5. The common structure of the nuclear steroid/thyroid hormone superfamily. The amino 
terminal (A/B), the DNA-binding domain (C/D) and ligand-binding domain (E/F). ERα – estrogen 
receptor α, ERβ – estrogen receptor β, ERα36 – estrogen receptor α36, PRA – progesterone receptor 
A, PRB – progesterone receptor B, AR – androgen receptor, THRα – thyroid hormone receptor α, 
THRβ – thyroid hormone receptor β. 
 
1.2.1.1 Estrogen receptors 
Estrogen is crucial for endometrial proliferation and vascularization and exerts its function 
via specific estrogen receptors (Smith, 2001;  Giudice, 2006). In 1986 the first estrogen 
receptor (ERα) was cloned (Green et al., 1986;  Greene et al., 1986). For a long time it 
remained the only known ER. However, in 1996 a second estrogen receptor (ERβ) was 
identified (Kuiper et al., 1996). Both receptors, ERα and ERβ, can bind estradiol with similar 
affinity and have been shown to be present in the human endometrium. Their expression is 
cycle-dependent and sex steroid hormone regulated (Giudice, 2006). Expression of ERα and 
ERβ in the epithelial cells increases during the proliferative phase, reaches its peak in the late 
proliferative phase and gradually decreases during the secretory phase in preparation for 
embryo implantation (Giudice, 2006). In the mid-secretory phase, expression of ERα in the 
stroma decreases under the regulatory effect of progesterone while the expression of ERβ is 
maintained, making ERβ a predominant receptor of the late secretory phase in the stromal 
compartment of the endometrium (Hapangama et al., 2014) (Figure 6). 
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Figure 6. Dynamics of estrogen receptor α (ERα) and estrogen receptor β (ERβ) expression in the 
epithelial and the stromal compartments of the endometrium during the menstrual cycle. 
 
Although ERα and ERβ share a common structure, their function in the endometrium is 
distinct in terms of gene regulation and consequently in biological response. While ERα 
promotes proliferation of the endometrium, ERβ counteracts estrogen mediated effects, 
providing protection against ERα induced hyperstimulation (Hapangama et al., 2014). Loss 
of ERβ have been suggested to be an important step in estrogen-dependent tumor progression 
(Bardin et al., 2004). An increase of the ERα/ERβ ratio was shown in several cancers as 
compared to normal tissue, including breast and ovary cancers (Bardin et al., 2004). 
Therefore an imbalance in the expression of ERα and ERβ may play a role in endometrial 
proliferative abnormalities and should be of special interest to study.  
1.2.1.2 G protein coupled estrogen receptor-1 
While nuclear ERs have been widely investigated in the human endometrium, the role and 
regulation of the receptors involved in the immediate, non-genomic, responses are largely 
unknown. Nearly 50 years ago, it was reported that the intracellular concentration of cAMP 
increases immediately after estrogen stimulation (Szego and Davis, 1967). The discovery of 
the membrane bound receptors that bind estrogens opened new possibilities to explain these 
rapid non-genomic effects. G-protein coupled estrogen receptor-1 (GPER), formerly referred 
to as GPR30, was first described in 1996 (Owman et al., 1996), however its ER properties 
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were demonstrated later in 2005 (Revankar et al., 2005;  Thomas et al., 2005). GPER belongs 
to the family of 7-transmembrane G protein – coupled receptors and is localized to the cell 
membrane and endoplasmic reticulum (Thomas et al., 2005;  Funakoshi et al., 2006;  Otto et 
al., 2008) (Figure 4). Its expression is cycle dependent and proposed to be regulated by 
ovarian steroid hormones in a similar way as ERα and ERβ, with up-regulation in the 
proliferative phase as a response to the rising levels of estradiol and down-regulation in the 
secretory phase due to increasing levels of progesterone (Kolkova et al., 2010;  Prossnitz and 
Barton, 2011;  Plante et al., 2012) (Figure 7).  
                        
Figure 7. Dynamics of GPER expression during the normal menstrual cycle. 
 
GPER is proposed to regulate cell growth and proliferation through functional cross-talk with 
ERα. Both receptors have been shown to be co-expressed in the epithelial and stromal 
compartments of the normal human endometrium (Kolkova et al., 2010). Functional cross-
talk between these two receptors was demonstrated in the studies where GPER expression 
together with ERα was required for estrogen-induced activity in cancer cells (Albanito et al., 
2007) and inhibition of ERα mediated effects in endometrial epithelial cells (Gao et al., 
2011). Thus, the identification of GPER opens new approaches in the understanding of 
estrogen mediated effects in the endometrium and the possible abnormalities that is 
associated with estrogen hyperstimulation. 
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1.2.1.3 Estrogen receptor α36 
ERα36 is a newly described variant of ERα which is lacking the transcriptional activation 
domains (AF-1 and AF-2) but maintains DNA-binding and partially, ligand-binding domains 
(Gu et al., 2014) (Figure 5). It was cloned and found to be localized in both cell membrane 
and cytoplasm mediating non-genomic estrogen signaling (Wang et al., 2006). The GPER 
specific agonist G1 was shown to bind ERα36 and to promote its activities (Kang et al., 
2010). The expression of ERα36 in the endometrium during the menstrual cycle is largely 
unknown. However, the expression of ERα36 in endometrial cancer tissue was found to be 
lower as compared to normal tissues (Sun et al., 2013). Moreover, lower expression of 
ERα36 was associated with endometrial hyperplasia in women with polycystic ovary 
syndrome (PCOS) (Lin et al., 2013). The higher proliferation activity associated with lower 
expression of ERα36 can be explained by inhibition of the transcriptional activity promoted 
by AF-1 and AF-2 domains of ERα (Wang et al., 2006). Thus, low expression of ERα36 may 
be associated with endometrial hyperplasia and further studies are needed to clarify its 
function and role in the endometrium (Lin et al., 2013).  
1.2.1.4 Progesterone receptors 
Progesterone actions are mediated via two nuclear receptors, PRA and PRB. These two 
isoforms have been found to be expressed in the epithelial and stromal cells of the 
endometrium (Critchley and Saunders, 2009). Several studies suggest that PRA and PRB 
display different functions. PRA was proposed to be a transcriptional inhibitor of PR-B when 
the two receptors are co-expressed (Giangrande and McDonnell, 1999). Moreover, animal 
studies have demonstrated that mice lacking PRA, but not PRB, fail to inhibit estrogen-
induced proliferation (Conneely et al., 2002), which may suggest a key role for PRA in 
endometrial function. Both isoforms are expressed in the endometrium in a cyclic manner.  
During the proliferative phase, expression of PRA and PRB increases in response to the 
rising levels of estradiol. Importantly, PRA is the predominant PR in the stromal 
compartment of the proliferative endometrium (Li et al., 2014). During the secretory phase, 
PRA and PRB expression gradually decreases in the epithelial compartment of the 
endometrium in response to increased progesterone levels (Li et al., 2014). However, a 
different situation is observed in the stromal compartment where expression of PRA remains 
unchanged while PRB is decreasing (Li et al., 2014) (Figure 8).  
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 Figure 8. Dynamics of progesterone receptor A (PRA) and B (PRB) expression during the normal 
menstrual cycle. 
 
1.2.1.5 Androgen receptor 
The main androgens that can be found in the blood circulation of women are: testosterone, 
androstenedione, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate 
(DHEAS) and dehydrotestosterone (DHT). DHT and testosterone are the major ligands for 
the androgen receptor (AR), while other androgens act as prohormones (Cloke and Christian, 
2012). DHT has a higher affinity for AR than testosterone. Endometrial levels of testosterone, 
androstenedione and DHEA can be higher as compared to blood levels and are increasing in 
the secretory phase of the menstrual cycle (Cloke and Christian, 2012). Interestingly, 
expression levels of different enzymes that are important for conversion of androgens are also 
higher in the endometrium during the secretory phase of the menstrual cycle, leading to the 
subsequent production of testosterone and DHT that can bind AR (Cloke and Christian, 
2012). 
AR has been found in the stromal and epithelial compartments of the human endometrium 
(Mertens et al., 2001). Endometrial AR shows variation in expression during the menstrual 
cycle with a gradual decrease from the early proliferative phase to the mid-secretory phase 
(Mertens et al., 1996) (Figure 9). 
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Figure 9. Dynamics of androgen receptor (AR) expression during the normal menstrual cycle. 
 
In vitro studies of stromal and epithelial cells have revealed that AR is positively regulated by 
estrogens and androgens, but down-regulated by progesterone (Apparao et al., 2002). 
Furthermore, AR expression increases following the administration of the anti-progestin 
mifepristone, in both human and primate endometrium (Slayden et al., 2001). There is an 
increasing body of evidence suggesting that androgens can counteract trophic effects of 
estrogens. After androgen administration endometrial atrophy was observed in female 
transsexuals (Miller et al., 1986). Moreover, our group has previously demonstrated that 
testosterone administration to postmenopausal women does not stimulate proliferation of the 
endometrium but rather counteracts estrogen-induced effects (Zang et al., 2007).  
1.2.2 Thyroid hormone receptors in human endometrium 
Production of thyroid hormones is controlled by the thyroid-stimulating-hormone (TSH) 
which is released from the pituitary gland  in response to production of thyrotropin-releasing 
hormone (TRH) from the hypothalamus (Speroff and A.Fritz, 2005) (Figure 10). TSH is 
regulating iodine uptake by the thyroid gland and coupling iodine to thyroglobulin (Speroff 
and A.Fritz, 2005) (Figure 10). 
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Figure 10. Regulation of thyroid hormone production. 
 
The thyroid gland is a butterfly shaped organ that is situated on the front of the neck and is 
producing thyroxin (tetraiodotyrosine, T4) and triiodothyronine (T3). Thyroid hormones are 
important regulators of growth and metabolism (Yen, 2001). Thyroid dysfunction is a 
condition known to be associated with abnormal pubertal development, menstrual 
irregularities, infertility and increased frequency of miscarriages, which suggest an important 
role for thyroid hormones in reproductive function (Poppe and Velkeniers, 2004). Moreover, 
thyroid dysfunction is more common in women as compared to men. However, the reason 
behind this sex difference is still unknown.  
In the circulation, approximately 70% of  thyroid hormones are bound to thyroxin-binding 
globulin (TBG) which is produced in the liver  (Speroff and A.Fritz, 2005). The secretion of 
TBG can be increased by estrogens. Although T4 is the principle hormone that is produced 
by the thyroid gland, T3 is much more portent and all thyroid actions in the body can be 
attributed to its activity (Speroff and A.Fritz, 2005). 
In peripheral tissues, T4 can be deiodinated to T3 by peroxidase enzymes, called 
iodothyronine deiodinases. Several types of iodothyronine deiodinase have been identified: 
type I iodothyronine deiodinase (DIO1), type II iodothyronine deiodinase (DIO2) and type III 
iodothyronine deiodinase (DIO3) (Yen, 2001). While DIO1 and DIO2 promote the activation 
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of the prohormone T4 to T3, DIO3 catalyzes inactivation of T3 and T4 (Yen, 2001;  Huang et 
al., 2003). All three enzymes were found to be present in the human endometrium, raising the 
possibility of thyroid hormone conversion in this tissue (Aghajanova et al., 2011).  Moreover, 
mRNA expression of the deiodinases was lower in the mid-secretory phase compared to the 
other phases of the menstrual cycle (Aghajanova et al., 2011). Lower expression in the luteal 
phase may be attributed to the rising levels of progesterone. 
1.2.2.1 Thyroid hormone receptors 
The genomic actions of thyroid hormones are mediated via the nuclear thyroid hormone 
receptors (THRα1, THRα2, THRβ1 and THRβ2) (Zhang and Lazar, 2000) (Figure 5). In 
contrast to other thyroid hormone receptors, THRα2 is not able to bind T3 and its role is 
largely unknown (Cheng, 2005).  
Thyroid hormone receptors have been found to be present in human endometrial and ovarian 
tissues (Aghajanova et al., 2011). The immunostaining of THRα1 and THRβ1 in the 
epithelial compartment of the human endometrium have been found to be significantly higher 
in the mid-secretory phase of the menstrual cycle as compared to the early secretory phase 
(Aghajanova et al., 2011). This result is further supported by the study where the 
administration of mifepristone resulted in down-regulation of THRα1 and THRα2 mRNA 
expressions and up-regulation of THRβ1 mRNA expression in the human endometrium 
(Catalano et al., 2007). These findings suggest a possible role of progesterone in the 
regulation of THR expression in the human endometrium (Catalano et al., 2007). 
In an in vitro study where endometrial and Ishikawa cells were used, the authors raised the 
suggestion that T3 and T4 can be produced by endometrial cells (Aghajanova et al., 2011). 
Taking into account that the different factors required for thyroid hormone synthesis have 
been found to be present in the human endometrium, it is likely that thyroid hormones are 
produced locally in this tissue. Moreover, the stimulation of Ishikawa and endometrial cells 
by TSH resulted in an increase of T3 and T4 levels (Aghajanova et al., 2011). 
The role of thyroid hormones in the endometrium is largely unknown. However, several in 
vitro studies propose the possible role of TSH and thyroid hormones in the regulation of 
endometrial glucose transport via glucose transporters, in particularly glucose transporter 1 
(GLUT1) (Hosaka et al., 1992;  Weinstein and Haber, 1993;  Aghajanova et al., 2009). 
GLUT1 expression in the human endometrium is higher compared to the other glucose 
transporters and might be essential for decidualization of stromal cells (Frolova and Moley, 
2011).  
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1.2.2.2 Thyroid stimulating hormone receptor and thyrotropin-releasing hormone 
receptor 
The respective receptors for TSH and TRH belong to the G - protein coupled receptor family. 
The thyroid stimulating hormone receptor (TSHR) has been shown to be present in human 
endometrium (Aghajanova et al., 2011). Its immunostaining in the glandular epithelium was 
found to be higher during the proliferative phase of the menstrual cycle as compared to the 
secretory phase (Aghajanova et al., 2011). However, in the luminal epithelium a more intense 
staining was observed in the mid-secretory phase as compared to the early secretory phase 
(Aghajanova et al., 2011).  
The role of TSH and TRH in the endometrium has not been thoroughly investigated. 
However the stimulation of Ishikawa cells and endometrial cells by TSH resulted in secretion 
of thyroid hormones. This may indicate functionality of TSHR and its possible involvement 
in endometrial physiology (Aghajanova et al., 2011).  
1.2.3 Insulin signaling in human endometrium 
Cyclical changes in the endometrium are dependent on glucose metabolism and adequate 
glucose supply (Schulte et al., 2015). Specifically, the endometrium needs to accumulate 
glycogen in the epithelial cells in preparation for embryo implantation. 
Insulin is a key player in the regulation of energy metabolism. It can modify glucose 
homeostasis by stimulation of glucose uptake (Diamanti-Kandarakis and Dunaif, 2012). 
However, only physiological levels of insulin may have a beneficial effect on the endometrial 
energy homeostasis. In vitro, insulin was shown to inhibit the insulin like growth factor 
binding protein I (IGFBP-1) which is produced by endometrial stromal cells and a well-
recognized biomarker of decidualization (Giudice et al., 1992). Thus, hyperinsulinemic 
conditions may adversely affect the metabolic state of the endometrium.  
The human endometrium expresses molecules that are required for insulin-signaling, 
including the insulin receptor (IR), insulin receptor substrate (IRS) and insulin glucose 
transporters, GLUT1, GLUT3 and GLUT4 (Mioni et al., 2012;  Shang et al., 2012).  
1.2.3.1 Insulin receptor 
The insulin receptor consists of two linked dimers: the extra-cellularly located α-subunit with 
a ligand-binding domain and the β subunit, which crosses the membrane and contains an 
intrinsic protein kinase activity (Diamanti-Kandarakis and Dunaif, 2012). After insulin 
binding, the β subunit of the receptor undergoes auto-phosphorylation which leads to its 
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activation and further phosphorylation of different substrates, including IRS1. Activated IRS 
can recruit a number of signaling molecules that promote GLUT4 translocation from the 
intracellular vesicles to the cell surface (Diamanti-Kandarakis and Dunaif, 2012) (Figure 11). 
              
 
Figure 11. The insulin receptor pathway. Activation of phophatidylinositide 3- kinases (PI3K ) results 
in the phosphorylation of membrane phospholipids and further recruitment of the 3-phosphoinositide-
dependent protein kinases (PDK). These kinases activate the serine/threonine kinases Akt/protein 
kinase B (PKB) and further mediate GLUT4 translocation to the membrane.  
 
Although all molecules that are important for insulin signaling have been demonstrated in the 
endometrium, the understanding of their regulation is far from complete. The insulin receptor 
was found in all endometrial compartments with a higher expression in the secretory phase of 
the menstrual cycle as compared to the proliferative phase which may indicate progesterone 
dependent regulation (Giudice, 2006;  Mioni et al., 2012). Results from in vitro studies have 
shown that both estrogen and progesterone can increase IR mRNA expression in cultured 
stroma cells (Strowitzki et al., 1993). Moreover, this reaction can be amplified when 
progesterone is added after estrogen priming (Strowitzki et al., 1993) (Figure 12). 
 
 16 
                           
Figure 12. Dynamics of the expression of insulin receptor (IR), glucose transporter 1 (GLUT1) and 
glucose transporter 4 (GLUT4) during the normal menstrual cycle as described by Mioni et al. (Mioni 
et al., 2012).  
 
Several glucose transporters, both insulin-dependent and -independent, have been reported to 
be present in the human endometrium. GLUT4 belongs to the insulin-dependent transporters, 
while GLUT1 located on the surface and inside the cell, represents insulin-independent 
glucose transporters (Mioni et al., 2012). GLUT4 immunostaining was mainly localized in 
the epithelial compartment of the endometrium with the expression higher during the 
proliferative phase as compared to the secretory phase (Mioni et al., 2012) (Figure 12). 
Moreover, testosterone was found to down-regulate GLUT4 mRNA expression in the 
endometrium (Zhang and Liao, 2010). 
GLUT 1 plays an important role in basal glucose uptake and storage. It was proposed to be 
the main glucose transporter in stromal cells of human endometrium (Frolova and Moley, 
2011). GLUT1 expression increases during the secretory phase and reaches maximum in the 
decidualized endometrium (Frolova and Moley, 2011;  Mioni et al., 2012) (Figure 12). 
1.2.4 Hormonal treatment and the endometrium 
In everyday clinical practice, a great range of hormonal preparations are used for 
contraception, and treatment of menstrual irregularities and climacteric symptoms. However, 
  17 
they all are different and therefore the effect on the endometrium is largely dependent on the 
type, dose and regimen used. 
1.2.4.1 Estrogens 
There are several types of estrogens used for hormonal treatment, such as estradiol, estriol 
and ethinyl estradiol. It is well established that long-term estrogen treatment alone increases 
the risk of endometrial hyperplasia and carcinoma (Grady et al., 1995). To avoid the 
stimulatory effect of estrogen on the endometrium, progesterone addition is compulsory to all 
women with intact uterus. 
1.2.4.2 Progestogens 
Besides natural progesterone, there is a great variety of synthetic progesterone preparations 
(progestogens) available, such as medroxyprogesterone acetate. Depending on their structure 
and binding capacity, synthetic progestogens can promote progesterone-like, anti-androgenic 
or androgen-like effects. However, all of them can induce secretory transformation of the 
endometrium and thereby exert anti-proliferative effects on the endometrium (Pike and Ross, 
2000).  
1.2.4.3 Tibolone 
Tibolone is a synthetic steroid, which was developed in the interest of optimizing the 
beneficial effects and safety of hormone treatment. In the body it is converted to three major 
metabolites: two have estrogenic effects (3α and 3β-hydroxy-TIB) and one promotes 
progestogenic and androgenic effects (∆4 isomer) (Hammar et al., 2007). Lower bleeding 
incidence with tibolone as compared to conventional hormone treatments has been reported 
(Hammar et al., 2007).  
1.2.5 An animal model to study primate endometrium 
Studies on the endometrium are not always possible to perform in women. Therefore it is 
important to use as appropriate animal model as possible. The rodent model is widely used, 
however there are fundamental structural and functional differences of the endometrium 
between the species that makes this model hard to translate and validate to humans. For 
example, rodents can have eight to twelve ovulations per cycle while humans have only one. 
Hence, the primate model seems to be more relevant to humans when it comes to studying 
the reproductive system (Cline et al., 2008).  
The cynomolgus macaque (Macaca fasicularis) (Figure 13) is a non-human primate with 
well described similarities to humans in terms of female reproductive biology. Female 
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macaques have the similar peripheral steroid hormone metabolism, structure of the 
endometrium, endometrial response to exogenous estrogens and sex steroid hormone receptor 
expression as humans (West and Brenner, 1983;  Brenner et al., 1990). They have 28 to 30 
day long menstrual cycles, single-egg ovulation and single off-spring delivery, distinct 
menarche and menopause, at 3 and 20 years of age respectively (Cline et al., 2008). Their 
similarity to humans makes the non-human primates a suitable model for endometrial studies.  
 
Figure 13. The cynomolgus macaque. 
 
1.3 ENDOMETRIAL DYSFUNCTION 
Human endometrium undergoes specific changes during each menstrual cycle. All those 
changes are hormone dependent and metabolically demanding (Schulte et al., 2015). Thus, 
any hormone or metabolic disturbance may affect the endometrium adversely leading to 
abnormalities and poor reproductive outcome. PCOS and thyroid gland dysfunction are 
associated with hormonal and metabolic abnormalities that may affect the endometrium 
adversely, leading to alterations in its functions and receptivity.  
1.3.1 Polycystic ovary syndrome 
PCOS is one of the most common endocrine disorders in women of reproductive age, with a 
reported prevalence as high as 15% (Fauser et al., 2012). PCOS is commonly associated with 
infertility and metabolic disorders. Its clinical manifestations may include menstrual 
irregularities, signs of androgen excess (hirsutism), overweight and obesity. Independent of 
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obesity, women with PCOS often present insulin resistance and hyperinsulinemia (Diamanti-
Kandarakis and Dunaif, 2012).  
Ovarian hyperandrogenism is the common feature and the biochemical hallmark of the 
syndrome (Azziz et al., 2009). Androgen excess may produce abnormalities in the feedback 
control of pulsatile gonadotropin releasing hormone (GnRH) secretion from the 
hypothalamus. In women with PCOS, relatively low levels of progesterone, resulting from 
infrequent ovulations, may play a role in the persistently rapid GnRH pulse frequency, 
elevated levels of LH and relative FSH deficiency. LH stimulates the ovarian theca cells, 
leading to an increase in androgen levels which establishes a vicious circle. Moreover, 
hyperinsulinemia, resulting from insulin resistance, can increase circulating androgen levels 
(Micic et al., 1988), without affecting gonadotropin (FSH and LH) secretion (Dunaif and 
Graf, 1989). Insulin was shown to affect androgen production directly by stimulating theca 
cells (Nestler et al., 1998) and indirectly by inhibiting the hepatic production of sex hormone-
binding globulin (SHBG) (Giallauria et al., 2009;  Dumesic and Richards, 2013). 
The etiology of PCOS is largely unknown, but a multi-factorial background including genetic 
factors (Legro et al., 1998;  Kahsar-Miller et al., 2001), androgen stimulation/programming 
in utero (Sir-Petermann et al., 2002), as well as lifestyle factors (Harwood et al., 2007) has 
been suggested.  
Reproductive disorders in women with PCOS have mostly been explained by anovulation but 
there is increasing evidence that the endocrine and metabolic abnormalities that are present in 
PCOS may have complex effects also on the endometrium, as revealed by altered receptivity, 
implantation failure and increased incidence of endometrial cancer in these women (Giudice, 
2006;  Shang et al., 2012).  
Insulin resistance and subsequent hyperinsulinemia that is present in PCOS was proposed to 
have an adverse effect on the endometrium (Schulte et al., 2015). Several molecules involved 
in the insulin pathway, including IRS1 and GLUT4 have been found to be reduced in the 
endometrium of obese women with hyperinsulinemia and PCOS (Mozzanega et al., 2004;  
Fornes et al., 2010;  Kohan et al., 2010;  Rosas et al., 2010;  Mioni et al., 2012). Moreover, 
insulin-resistant women with PCOS have a significant decrease in implantation and 
pregnancy rates as compared to non-hyperinsulinemic women with PCOS (Chang et al., 
2013). In women with PCOS, embryo development is not affected, indicating that it is the 
impaired endometrial receptivity that plays a role in the poor reproductive outcome in those 
women. Furthermore, the insulin-sensitizing drug, metformin was found to promote positive 
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effects on endometrial insulin signaling in women with PCOS (Zhai et al., 2012;  Carvajal et 
al., 2013). However, the role of insulin signaling in the endometrium as well as the relation to 
reproductive function in women with PCOS needs further investigation. 
In the absence of ovulation and the regulatory effects of progesterone, the endometrium does 
not undergo secretory transformation and is continuously exposed to the stimulatory and 
mitogenic effects of estradiol that can lead to endometrial overgrowth and hyperplasia (Elliott 
et al., 2001). In women with PCOS, ERα expression in proliferative and secretory 
endometrium was found to be higher as compared to healthy controls (Gregory et al., 2002;  
Maliqueo et al., 2003;  Quezada et al., 2006;  Villavicencio et al., 2006). However, one study 
showed that expression of ERα, ERβ and GPER during the window of implantation was 
lower in PCOS women, as compared to controls (Wang et al., 2011). Limited data is 
published regarding the role of ERα36 in the endometrium of patients with PCOS. In a recent 
study, ERα36 expression was shown to be lower in the proliferative endometrium of PCOS 
women as compared to the control group (Lin et al., 2013). Considering limited and 
conflicting data regarding estrogen signaling in the endometrium of PCOS women, further 
studies are needed to clarify ER expression, distribution and importance for reproductive 
function.  
Approximately 40-60% of PCOS women are obese (Ehrmann et al., 2006). Obesity can 
aggravate insulin resistance and thereby worsen reproductive dysfunction in women with 
PCOS (Ehrmann et al., 2006;  Hirschberg, 2009). Several studies have shown that even a 5-
10% loss in body weight can improve menstrual cyclicity and restore ovulation in PCOS 
women (Hoeger et al., 2004;  Tolino et al., 2005;  Palomba et al., 2008;  Thomson et al., 
2008;  Moran et al., 2009). Moreover, our group has demonstrated that diet and exercise 
alone or in combination can improve reproductive function in overweight/obese women with 
PCOS (Nybacka et al., 2011). Thus, lifestyle modification aiming at weight loss is the first-
line choice of treatment to improve reproductive and metabolic health in women with PCOS. 
However, the effect of lifestyle intervention on endometrial function has not been previously 
studied. 
1.3.2 Thyroid dysfunction  
Thyroid dysfunction is a condition known to reduce the likelihood of pregnancy (Poppe and 
Velkeniers, 2004). Both hyperthyroidism, with suppressed levels of TSH and increased T3 
and T4 production, and hypothyroidism, with elevated levels of TSH, are associated with 
menstrual disturbances and reproductive dysfunction. The prevalence of hyperthyroidism in 
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the general population is approximately 1.5%, while hypothyroidism comprises from 2% - 
4% in reproductive age women (Poppe and Velkeniers, 2004). 
Hypothyroid women exhibit a number
 
of reproductive disorders, including menstrual cycle 
aberration and infertility (Poppe and Velkeniers, 2004). The most common cause of 
hypothyroidism is autoimmune thyroiditis, which incidence was demonstrated to be threefold 
higher in women with PCOS (Janssen et al., 2004). The increased prevalence of autoimmune 
thyroiditis in PCOS women was suggested to be in part due to some common genetic defect, 
however other factors cannot be excluded (Janssen et al., 2004). Moreover, hypothyroidism 
was found to be associated with insulin resistance in muscle and adipose tissues (Dimitriadis 
et al., 2006). An association between TSH levels and insulin resistance in PCOS women, 
independent of age and body mass index (BMI), have also been reported (Mueller et al., 
2009). In an animal study, thyroid hormone treatment of obese diabetic rodents increased 
insulin sensitivity and reduced hyperglycemia and hyperinsulinemia (Koritschoner et al., 
2001). Thus, evidence from animal and human studies proposes that insulin resistance in 
PCOS women could be enhanced in the presence of thyroid gland dysfunction. 
The TSHR as well as THRs are expressed in the human ovary and endometrium (Aghajanova 
et al., 2009;  Aghajanova et al., 2011) indicating that the corresponding hormones might 
exert direct effects on endometrial function. Their expression in the human endometrium has 
been sparsely studied and proposed to vary during the menstrual cycle, depending on sex 
hormone secretion (Catalano et al., 2007;  Aghajanova et al., 2011). Thus, disturbed 
production of sex steroid hormones observed in women with PCOS may adversely affect 
thyroid hormone signalling in the endometrium, contributing to the reproductive dysfunction. 
However, the effects of sex steroid hormones on the regulation of factors involved in thyroid 
hormone action in the endometrium remains to be established. 
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2 AIMS 
The overall aim of this thesis was to increase the understanding of hormonal receptor 
regulation of the primate uterus, and in particular to investigate the effects of different 
hormone treatments and lifestyle intervention on endometrial receptor expression. 
Specific aims of the study: 
I. To study the effects of long-term sex hormone treatment including tibolone on uterine 
expression and distribution of the estrogen receptors (ERα, ERβ, GPER), the 
progesterone receptors (PRA, PRB) and the androgen receptor (AR) in the 
cynomolgus macaque. 
II. To investigate the effects of long-term sex hormone treatment on the expression, 
distribution and regulation of the receptors for TRH, TSH and thyroid hormones in 
monkey uterus. 
III. To explore the effects of lifestyle intervention aiming at weight loss on the expression 
of molecules involved in insulin signaling in the endometrium of overweight/obese 
women with PCOS. 
IV. To study receptors of genomic and non-genomic estrogen signaling in relation to 
proliferation activity in the endometrium of women with PCOS as compared to BMI-
matched controls. 
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3 MATERIAL AND METHODS 
The thesis includes methods from studies where an animal model was used (paper I and paper 
II) and clinical investigations were performed (paper III and IV).  
3.1 PAPER I AND II 
3.1.1 Animals in paper I and II 
Female adult cynomolgus macaques (Macaca fasciculais) (Figure 13) ranging from 6 to 8 
years of age were imported from Indonesia to the United States. Animals were housed in 
social groups of four to six monkeys each. Each animal underwent clinical assessment and 
determined to be healthy. 
Three months before initiation of treatment all animals were ovariectomized. Each social 
group was randomly assigned to oral treatment for 24 months with conjugated equine 
estrogens (CEE) alone or in combination with medroxyprogesterone acetate (MPA) or with 
tibolone (TIB) (Figure 14). The control group received no hormonal treatment (OvxC). The 
animals were treated, with doses corresponding to those given to women and in relation to 
body weight. Thus, the daily dose was designed to correspond to 0.625 mg CEE, 2.5 mg 
MPA, and 3 mg TIB. The animals were treated twice daily with the dose split between 
feedings. At the end of the treatment uterine tissues were obtained from 88 monkeys (OvxC, 
n=20; CEE, n=20; CEE+MPA, n=20; TIB, n=28) (Figure 14).  
 
Figure 14. Schematic diagram of the study plan. 
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The study was approved by the Institutional Animal Care and Use Committee of Wake Forest 
University (A96-155; A93-116).  
3.1.2 Tissue collection in paper I and II 
Uterine tissues were fixed in 4% paraformaldehyde for 24 hours and transferred to 70% 
ethanol for further storage and paraffin embedding. The paraffin blocks of the uteri were 
sectioned at 5 µm for immunostaining. 
3.1.3 Determination of hormone levels in paper II 
Serum levels of TSH and T4 were evaluated using an immunoradiometric assay (IRMA) and 
radioimmunoassay (RIA) kit, respectively, from Diagnostic Products Corp. (Los Angeles, 
CA); TSH, Cat#IKTS1; and free T4, Cat#TKT41. The determinations of hormone levels 
were performed at Biomarkers Core Lab Yerkes (National Primate Research Center, Emory 
University, Atlanta, GA). 
3.2 PAPER III AND IV 
3.2.1 Subjects in paper III and IV 
The clinical study was performed at the Women’s Health Research Unit at Karolinska 
University Hospital, Stockholm, Sweden. Women of reproductive age (18-40 years) with 
PCOS, and their controls, were recruited between 2008-2012 by clinical referral or 
advertisements in the local newspapers. Initial screening was performed by a nurse using a 
standardized telephone questionnaire. Those women that seemed eligible were scheduled for 
a visit to a gynecologist. The PCOS diagnosis was based on the Rotterdam criteria, i.e. oligo- 
or anovulation, hyperandrogenism and polycystic ovaries on ultrasound (Rotterdam, 2004). 
Women were eligible if they met all these three criteria. Additional inclusion and exclusion 
criteria are shown in Table 1. 
Table 1. Inclusion and exclusion criteria of PCOS women 
Inclusion criteria Exclusion criteria 
PCOS diagnosis based on the 
criteria 
Hysterectomy 
three Rotterdam criteria  Endometrial pathology at screening 
Otherwise healthy Intrauterine device 
Age 18-40 Steroid hormone treatment less than 3 months prior to the study 
study  
 Pregnancy or lactation during the preceding 12 months 
 Weight loss during the preceding 12 months 
 Virgo 
 Physical handicap 
 Eating disorders 
 Smoking, alcohol abuse, chemical dependence 
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In total 52 women, both those diagnosed with PCOS and their age- and BMI- matched 
regularly cycling controls, participated in the study. All women were divided into four groups 
according to PCOS diagnosis and BMI: 
 PCOS women with a BMI > 27 (OB-PCOS), n=20 
 Healthy control women with a BMI > 27 (OB-C), n=10  
 PCOS women  with a  BMI between 19 and 25 (NW-PCOS), n=11 
 Healthy control women with a BMI between 19 and 25 (NW-C), n=11  
Informed consent was obtained from all participants. The study was approved by the local 
ethics committee (Dnr 2008/865-32). 
3.2.2 The intervention in paper III and IV 
Women in the OB-PCOS group underwent three months of an individually adapted lifestyle 
intervention program. The aim of the program was weight reduction. To do so participants in 
the OB-PCOS group were closely supervised by a dietician and received a membership of a 
local gym network (Figure 15).  
The recommended diet was high in protein and low in carbohydrates (40E% carbohydrates, 
30E% fat, and 30E% proteins).  This diet has previously been shown to be efficient in women 
with PCOS and in maintenance of weight loss (Moran et al., 2003;  Larsen et al., 2010). A 
strict regimen of three main meals and two or three snacks were introduced to all women in 
the OB-PCOS group. Participants recorded and reported their food intake which was 
corrected if required. 
In order to increase physical activity all participants received a membership to a local gym 
network and a recipe of recommended physical activity (FaR
®
 – physical activity on 
prescription).  
FaR
® 
is a public health initiative to improve physical activity and reduce obesity in Sweden. 
It allows licensed medical personnel to prescribe physical activity to the patient and is proven 
to be effective in clinical settings (Kallings et al., 2008). In our study, type of training, its 
frequency and duration was recommended depending on each individual’s preferences, 
interest, experience and situation. An average physical activity consisted of aerobic activity 
for 45 min 2 or 3 times per week. Participation was recorded by the gym staff (Figure 15). 
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Figure 15. Schematic graph of the intervention program. 
3.2.3 Experimental design in paper III and IV 
All participants in paper III and IV underwent a general health examination including 
assessment of blood pressure, weight, height, and waist/hip ratio before and at the end of the 
intervention.  
Women in the OB-PCOS and NW-PCOS groups were initially anovulatory presenting either 
amenorrhea (no bleeding for the past 3 months) or oligomenorrhea (5-9 periods during the 
past year with intervals more than 6 weeks), while the women in the OB-C and NW-C groups 
had regular menstrual pattern.  
Women in the OB-PCOS group were examined before and after 3 months of lifestyle 
intervention on cycle day 6-8 and on cycle day 21-23 of the menstrual cycle as determined by 
spontaneous menstruation or by induced menstruation after progestogen test. 
A fasting blood sample was collected from a peripheral vein at 8.00 a.m. and stored at -70°C 
for analysis of hormones and binding proteins. In addition, gynecological examination, 
including transvaginal ultrasound was performed by the same investigator using Sonoline SL-
250 equipment (Siemens Healthcare Diagnostics).  
Endometrial biopsies were collected under local anesthesia using an endometrial suction 
curette (Pipet Curet, CooperSurgical, USA) for analysis of proteins and genes involved in 
insulin and steroid hormone signaling in the endometrium. The women in the OB-C, NW-
PCOS and NW-C groups were examined once at cycle day 6-8 and on cycle day 21-23 of 
the menstrual cycle (Figure 16). 
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Figure 16. Schematic diagram of the study plan.  
 
During the lifestyle intervention, the menstrual pattern of the women in the OB-PCOS 
group was recorded for further evaluation. Ovulation was confirmed on the bases of the 
elevated serum level of progesterone (>17nmol/l) in the luteal phase of the menstrual cycle. 
The menstrual pattern was considered to be improved when there was a shift from 
amenorrhea to oligomenorrhea/regular menstruation or from oligomenorrhea to regular 
menstruation.  
3.2.4 Tissue collection in paper III and IV 
All biopsies were divided into two pieces: one was preserved in RNAlater® for further 
isolation of RNA and the other one was first fixed in 4% phosphate buffered formaldehyde 
for 9h and then transferred to 70% ethanol for later embedding in paraffin. The endometrium 
was sectioned at 5µm for immunostaining. 
3.2.5 Determination of hormone levels in paper III and IV 
Serum concentrations of LH, FSH and SHBG were analyzed using chemiluminescent 
enzyme immunometric assays (EIA) while estradiol was measured by RIA. Serum 
concentrations of testosterone were analyzed by liquid chromatography (UPLC)/tandem mass 
spectrometry (LS-MS/MS). Detection limits and coefficient of variations are presented in 
Table 2. 
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Table 2.  Methods, detection limits, intra-and interassay coefficients of variation (CV) for 
hormones and SHBG. 
Analyte Method Detection limit Within assay CV Between assay CV 
LH EIA 0.7 IU/l 6.0% 9.0% 
FSH EIA 0.1 U/l 8.0% 8.0% 
Testosterone LC-MS/MS 0.1 nmol/l              overall 9.2% 
SHBG EIA 0.2 nmol/l 6.5% 8.7% 
Estradiol 
 
Progesterone 
RIA 
 
Progesterone 
5 pmol/l 
Progesterone 
3.0% 
 
Progesterone 
6.0% 
Progesterone 
Insulin RIA 
 
2.7 mIU/l 3.0% 4.0% 
 
Free testosterone was calculated from the serum concentrations of total testosterone and 
SHBG, utilizing a fixed albumin concentration 40g/l and successive computerized 
approximation involving a system of equation derived from the law of mass action. 
Glucose was assayed using the YSI 2300 STAT Plus 
TM
 Glucose & Lactate Analyzer (YSI, 
Inc., Life Science, Yellow Springs, OH, USA). 
Insulin resistance was assessed by the calculating the quantitative insulin sensitivity check 
index (QUICKI).  
  QUICKI = 1/(log(fasting insulin mIU/1) + log(fasting glucose, mmol/l)  
Insulin resistance is defined when QUICKI ≤ 0.33 
 
3.3 MOLECULAR BIOLOGY IN PAPER III-IV 
3.3.1 RNA extraction in paper III and IV 
Total RNA from endometrial biopsies were purified with RNeasy® Mini Kit (Qiagen GmbH, 
Hilden, Germany) in accordance to the manufacture’s protocol, including a DNase treatment 
step.  
Reverse transcription was performed using 2 µg of total RNA from each sample and the 
reaction mixture (Qiaqen) containing 1 x RT buffer, dNTP mix (0.5 mM each dNTP), 600 ng 
random primers (Invitrogen, Paisley, UK), 30 units RNase inhibitor (Qiaqen), and 4U of 
Omniscript
TM 
reverse transcriptase (Qiagen). A total volume of 20 µl was reverse transcribed 
at 37˚C for 60 min. The obtained cDNA was then stored at -70°C until further investigations. 
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3.3.2 Real time PCR analysis in paper III  
Taqman® assays for INSR, IRS1, GLUT1, GLUT4 and housekeeping gene RPL13A were 
purchased from Applied Biosystems.  Following assays were used: Hs00961554_ml for 
INSR, Hs00178563_ml for IRS, Hs00892681_ml for GLUT1, Hs01573827_ml GLUT4 and 
Hs01926559_ml for RPL13A. The real-time PCR was performed according to the 
manufacturer’s standard protocol. All reactions were carried out in triplicates with Taqman 
Universal PCR Master Mix (Applied Biosystems) in StepOnePlus
TM
 Real-Time PCR 
Systems (Applied Biosystems). The housekeeping gene RPL13A was used to normalize the 
mRNA levels of the gene of interest.  
3.3.3 Real time PCR analysis paper IV 
The oligonucleotide primers for ERα, ERβ, GPER, ERα36 and RPL13A (housekeeping gene) 
are presented in paper IV. This housekeeping gene was chosen because of its expression and 
minimal fluctuation in the endometrium. Real time PCR was performed in an iCycler
TM 
iQ 
Real Time PCR System (Bio-Rad Laboratories, Inc, CA, USA). 
A reaction volume of 25 µl was used, containing cDNA corresponding to 50 ng RNA for 
ERα and ERα36 or 100 ng for ERβ and GPER, 12.5 µl of iQTM SYBR® Green Supermix 
(Bio-Rad) and 0.3µM of each oligonucleotide primer. All measurements were performed in 
duplicates. 
An RNA sample without reverse transcription was used as a negative control. The melting 
curve was used to control the purity of PCR products. 
3.3.4 Immunohistochemistry in paper I, II and IV 
Immunostaining was performed on 5µm thick sections using a standard 
immunohistochemical technique (avidin-biotin-peroxidase). All sections were deparaffinized 
in xylene and rehydrated in graded ethanol. All sections were subjected to the antigen 
retrieval except those to be stained for TSHR. Antigen retrieval was achieved by boiling in 
0.01M citrate buffer (pH6.0) in a microwave oven. The endogenous peroxidase activity was 
blocked by treatment of 3% H2O2 in methanol. Before applying the primary antibody all 
slides were treated with 1.5% normal horse serum (NHS), 2% NHS or 5% NHS + 5% BSA. 
The primary antibodies and their dilutions are presented in Table 3. After the primary 
antibody the corresponding secondary antibody was applied, i.e. either horse anti-mouse IgG 
(BA-1400, Vector Laboratory) or horse anti-mouse/rabbit IgG (BS-1400, Vector Laboratory).  
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Immunostaining was performed using a Vectastain Elite ABC kit (Vector Laboratories Inc.) 
and diaminobenzidine (DAKOcytomation) as chromogen. The sections were counterstained 
with hematoxylin and dehydrated before mounted with Pertex (Histolab, Gothenburg, 
Sweden). The negative controls were obtained by replacing the primary antibody with the 
corresponding concentration of mouse or rabbit IgG. 
Table 3. The primary antibodies and dilutions. 
Protein Antibody  
Manufacturer 
Dilution 
Interassay 
CV 
Manufacturer 
 
ERα monoclonal 1:5 Zymed, 08-1149 
ERβ  monoclonal 1:20 Serotec, MCA 1974 
GPER polyclonal 1:250 Atlas, HPA027052 
PRA monoclonal 1:500 Novocastra, NCL-PgR312 
PRB  monoclonal 1:100 ABR, MAI-411 
AR polyclonal 1:200 DAKO, M 3562 
Syndecan-1 monoclonal 1:30 DAKO, M7228 
TRHR polyclonal 1:150 Gen Way, 18-461-10338 
TSHR monoclonal 1:500 MCA 1571, AbD Serotec 
THRα1/α2 monoclonal 1:200 Santa Cruz, SC-56874 
THRβ1 monoclonal 1:500 Santa Cruz, SC-737 
3.3.5 Immunohistochemistry in paper III 
Immunostaining was performed using paraffin sections, 5 µm thick. All sections were 
deparaffinized before antigen retrieval was performed in a 2100 autoclave (Prestige medical, 
Minworth, England) using Diva Decloaker
TM 
(Biocare Medical) and Hot Rinse
TM
 (Biocare 
medical) according to the manufacturer’s instructions. Endogenous peroxidase activity was 
blocked using undiluted Peroxidazed
TM 
(Biocare Medical) while non-specific binding was 
prevented by applying Background Sniper
TM
 (Biocare Medical). Thereafter the primary 
antibody was applied using the concentrations that are shown in Table 4. 
Table 4. The primary antibodies and dilutions. 
Protein Antibody  
Manufacturer 
Dilution 
Interassay 
CV 
Manufacturer 
 
INSR α subunit monoclonal 1:50 LifeSpan Biosciences, Seattle, WA, USA 
INSR β subunit monoclonal 1:100 LifeSpan Biosciences 
IRS1 polyclonal 1:200 Santa Cruz Biotechnology, Santa Cruz,CA USA 
GLUT1 monoclonal 1:400 LifeSpan Biosciences 
GLUT4 monoclonal 1:500 LifeSpan Biosciences 
pY612IRS1 polyclonal 1:2500 Abcam, Cambridge, UK 
pS312IRS1 polyclonal 1:500 MyBio source, San Diego, CA, USA 
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After the primary antibody, the corresponding secondary antibody was applied. The 
immunohistochemistry was performed using diaminobenzidine (DAKOcytomation) as 
chromogen. At the final step, sections were counterstained with hematoxylin, dehydrated in 
ethanol, rinsed in xylene and mounted with Pertex. To obtain a negative control the primary 
antibody was replaced by the corresponding concentration of mouse or rabbit IgG. 
3.3.6 Image analysis in paper II and IV 
A Leica microscope and Sony video camera (Park Ridge, NJ) connected to a computer with 
an image analysis system (Leica Imaging system Ltd, Cambridge, UK) were used to perform 
quantitative evaluation of the nuclear immunostaining (Figure 17). 
 
Figure 17. Representative image of ERα immunostainig in human endometrium. 
 
The quantification of immunostaining was performed in 10 randomly chosen fields. When 
less than 10 fields where available, all epithelia or stromal cells were used for evaluation. In 
short, an image analysis system using color discrimination software was used to calculate the 
total area of positively stained nuclei (brown) expressed as a ratio of the total area of cell 
nuclei (brown + blue negative). Luminal epithelium, glandular epithelium and stroma were 
evaluated separately (Figure 17). 
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3.3.7 Manual scoring of immunohistochemical staining in paper I - IV. 
The intensity and tissue distribution of cytosolic  immunostaining were manually and 
independently evaluated by two investigators blinded to the group  and order of sampling 
using a four-point grading scale: (-) negative, (+) faint, (++), moderate; and (+++) strong 
immunostaining. The correlation between the two observers with this method was 75% for 
the three tissue types (paper IV).   
3.3.8 Statistical analysis in paper I-IV 
All values are expressed as mean ± standard deviation (SD) or median and quartile range 
(P25-P75) depending on sample distribution. Differences within a group were analyzed with 
either paired t-test or the Wilcoxon matched pairs test depending on data distribution. 
Differences between more than two groups were evaluated by the Kruskal-Wallis test 
followed by Dunn’s test, whereas differences between two groups were performed by the 
Mann-Whitney U test. To examine if menstrual pattern, ovulation and insulin sensitivity were 
changed following lifestyle intervention, we used the sign test. 
Correlations between the variables were evaluated using the Spearman’s rank order 
correlation test. The significant level was set at p<0.05. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I AND II 
4.1.1 Sex hormone treatment and steroid hormone signaling in monkey 
uterus 
The primate endometrium is a sex hormone sensitive tissue. Sex hormones are regulating its 
transformation and function.  In everyday clinical practice, different hormonal preparations 
are used to treat menstrual irregularities and climacteric symptoms. The endometrial response 
to treatment depends on the type and the dose of the regimen used. New synthetic steroids are 
developed in order to optimize the beneficial effects in relation to risks associated with 
hormone treatment. TIB is a synthetic steroid, which mediates estrogenic, progestogenic and 
androgenic effects. In an animal model, long-term treatment with TIB resulted in lower 
bleeding incidence and endometrial proliferation as compared to conventional hormone 
treatment (Cline et al., 2002). This finding raised the hypothesis that TIB affects the 
endometrium differently from that observed by conventional treatment. However, the 
underlying mechanisms for the beneficial bleeding profile, as well as for the lower 
proliferation activity are largely unknown. In this study, we investigated the effects of 
conventional hormone treatment and TIB on the expression of sex steroid hormone receptors 
in monkey uterus.  
Estrogen receptors are important regulators of endometrial proliferation. We found 
immunostaining of ERα, ERβ and GPER in all compartments of monkey endometrium 
(Figure 18). 
 
Figure 18. Representative images of estrogen receptor α (ERα), β (ERβ) and G-protein coupled 
estrogen receptor-1 (GPER) immunostaining in the endometrium of the cynomolgus macaque. 
 
In the monkey uterus, the combined treatment with CEE+MPA resulted in down-regulation 
of ERα in luminal epithelium and in myometrium as compared to the TIB treated group and 
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controls (Figure 19). In the stromal cells, ERα immunostaining was lower in the TIB treated 
group as compared to the CEE treated group, but not different to the combined CEE+MPA 
treatment and the control group (Figure 19). Lower expression of ERα in the TIB group as 
compared to the CEE group can be attributed to the regulatory effect of its ∆4 isomer 
metabolite which has both progestogenic and androgenic effects. Loss of ERβ expression was 
proposed to be associated with estrogen-dependent tumor progression (Bardin et al., 2004). 
Expression of ERβ in the epithelial compartment and myometrium was not different between 
the treatment groups. Overall, we have demonstrated that TIB treatment was not different 
from the control group in regard to ERα and ERβ expression, while combined CEE+MPA 
treatment affected ERα and ERβ immunostaining in the monkey endometrium.  
 
Figure 19. Expression of estrogen receptor α (ERα) and β (ERβ), G-protein-coupled estrogen 
receptor-1 (GPER), progesterone receptors A (PRA) and B (PRB) and androgen receptor (AR) in the 
monkey endometrium after long-term sex hormone treatment. ∆ - weak staining, ∆∆- moderate 
staining and ∆∆∆- strong staining; as compared to the other groups. Results with different letter 
designations are significantly different (p<0.05). Those with a common letter are not significantly 
different.  
 
GPER immunostaining in the luminal epithelium and myometrium was not affected by sex 
hormone treatment. However in glandular epithelium, treatment with CEE and TIB resulted 
in increased GPER immunostaining as compared to the combined treatment with CEE+MPA 
but not in comparison to the control group (Figure 19). In the stromal cells, combined 
treatment with CEE+MPA resulted in an increase of GPER immunoreactivity as compared to 
the control group (Figure 19). TIB treatment had no effect on GPER immunostaining in 
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monkey endometrium when compared to the controls (Figure 19). Our findings may suggest 
that unchanged protein expression of ERα, ERβ and GPER in the TIB group as compared to 
the controls, is a part of the mechanism behind the low endometrial proliferation associated 
with this treatment.  
PRA and PRB promote anti-proliferative action on the human endometrium (Graham and 
Clarke, 1997). Thus, loss of PRs may lead to estrogen-mediated endometrial proliferation. 
We found that the hormone treatments used did not reduce PR expression in the monkey 
endometrium but rather increased its expression in stroma, as well as in the myometrium.  
Several lines of evidence support an ability of androgens to counteract trophic effects of 
estrogens on the endometrium (Miller et al., 1986;  Brenner et al., 1990;  Zang et al., 2007;  
Zhang and Liao, 2010). AR immunostaining in the epithelial compartment of monkey 
endometrium was down-regulated by CEE and CEE+MPA treatments (Figure 20). In 
contrast, TIB treatment had minimal effect on AR expression in luminal and glandular 
epithelia which was comparable to that found in the control group (Figure 20). In the stromal 
compartment, TIB treatment resulted in up-regulation of AR as compared to CEE alone or 
control treatment (Figure 20). Thus, enhanced expression of AR after TIB treatment may be a 
mechanism which explains the endometrial atrophy in TIB users.  
 
Figure 20. Representative images of androgen receptor (AR) immunostaining in the endometrium of 
cynomolgus macaque after long-term sex hormone treatment. 
 
In conclusion, we have found that in contrast to CEE alone or combined CEE+MPA 
treatment, TIB has a minor effect on androgen signaling in the monkey endometrium. 
Moreover, TIB treatment resulted in up-regulation of AR in the stroma. Thus, lack of down-
regulated AR expression may be of importance for endometrial atrophy and beneficial 
bleeding profile associated with this treatment in comparison to conventional hormone 
treatment. 
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4.1.2  Sex hormone treatment and thyroid hormone signaling in monkey 
uterus 
Thyroid gland function is essential for reproduction. Disturbances in the thyroid hormone 
secretion are associated with menstrual irregularities, infertility, and increased frequency of 
miscarriage (Poppe and Velkeniers, 2002;  Poppe and Velkeniers, 2004). Since all receptors 
of thyroid hormone signaling, except TRHR, have been shown to be present in the human 
endometrium (Aghajanova et al., 2011), we hypothesized that the regulation of their 
expression can be sex steroid hormone dependent. We used an animal model to clarify the 
potential role of sex hormones in the regulation of the expression and distribution of TRHR, 
TSH, THRα1/α2 and THRβ1 in the primate uterus. 
We found that all receptors of the thyroid hormone system, i.e. TRHR, TSHR and THRs 
were present in all compartments of the primate uterus (Figure 21). 
 
Figure 21. Representative images of thyrotropin-releasing hormone receptor (TRHR), thyroid-
stimulating-hormone receptor (TSHR) and thyroid hormone receptor α (THRα) and β (THRβ) 
immunostaining in the endometrium (upper part) and myometrium (lower insert) of the cynomolgus 
macaque. 
 
Although the expression of TSHR and THRs have been described previously in the human 
endometrium (Aghajanova et al., 2011), we are the first to demonstrate that TRHR is also 
present in the primate endometrium. Thus, TRHR may have a direct effect on endometrial 
receptivity and function. TRHR expression in the primate endometrium was affected by long-
term sex hormone treatment. Combined treatment with CEE+MPA resulted in down-
regulation of TRHR in the luminal epithelium as compared to CEE alone treatment (Figure 
22). TRHR expression in glandular epithelium after CEE+MPA treatment was lower as 
compared to all other groups (Figure 22). However, in the stromal compartment, CEE+MPA 
treatment resulted in an up-regulation of TRHR expression as compared to the TIB treatment 
and the control group, indicating a different treatment response. A study on myometrial strips 
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showed that TRH promotes a relaxant effect on the human myometrium (Potter et al., 2004). 
Thus, TRH may have a direct effect on the primate uterus via its cognate receptor. The 
expression of TRHR was affected by sex hormone treatment. However, the role of TRH in 
the regulation of the primate endometrium is yet to be defined.  
 
Figure 22. Expression of thyrotropin-releasing hormone receptor (TRHR), thyroid stimulating 
hormone receptor (TSHR), thyroid hormone receptor α (THRα) and thyroid hormone receptor β 
(THRβ) in the monkey uterus after long-term sex hormone treatment. ∆ - weak staining, ∆∆- moderate 
staining  and ∆∆∆- strong staining; as compared to the other groups. Results with different letter 
designations are significantly different (p<0.05). Those with a common letter are not significantly 
different.  
 
TSHR immunostaining in the control group was higher in the epithelial compartment of the 
endometrium as compared to the stromal cells (Figure 22). This finding is in agreement with 
the data published on the human endometrium (Aghajanova et al., 2011). Expression of 
TSHR in the epithelial compartment was not different between the groups while in the 
stromal cells, immunostaining was higher in the group treated with CEE+MPA as compared 
to the controls (Figure 22). Furthermore, TSHR was found to be present in the myometrium 
where its expression was up-regulated by the TIB treatment as compared to the controls 
(Figure 22). Since TIB mediates estrogenic, progestogenic and androgenic effects it is hard to 
draw a clear conclusion via which of the steroid hormone receptors this effect is promoted on 
the myometrium. Interestingly, TSH levels correlated negatively with immunostaining of 
TSHR in the glandular epithelium and the myometrium. An increased risk of miscarriage 
have been reported in women with  hypothyroidism, who also are known to have high levels 
of TSH (Poppe and Velkeniers, 2002). We suggest that TSH can directly affect the 
endometrium and be involved in the mechanism for increased risk of miscarriage in women 
with thyroid gland dysfunction. 
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In the human endometrium, THRs have been found to be expressed in a cyclic dependent 
manner with an up-regulation in the secretory phase (Aghajanova et al., 2011). We found no 
difference in the expression of THRs in the luminal epithelium of monkey endometrium 
(Figure 22). However in glandular epithelium, immunostaining of THRβ was higher in the 
CEE treated group as compared to the TIB group (Figure 22). In the stromal cells, THRα 
expression was not affected by sex hormone treatment while in the myometrium it was lower 
in the CEE and CEE+MPA groups as compared to controls (Figure 22). THRβ 
immunostaining was lower in stroma of the CEE as compared to the TIB group (Figure 22). 
In the myometrial compartment, THRβ immunostaining was lower in the CEE+MPA group 
as compared to the TIB group and controls (Figure 22). Overall, our findings suggest that 
both estrogen and progesterone are involved in the regulation of THRs expression in the 
primate uterus. 
We have demonstrated that all receptors involved in thyroid hormone signaling are present in 
the primate uterus and that they are all regulated by sex hormone treatment. Our findings 
raise the possibility of direct actions of TRH, TSH and thyroid hormones on the function of 
the primate uterus. 
 
4.2 PAPER III AND IV 
4.2.1 Effects of lifestyle intervention on the expression of molecules 
involved in insulin signaling in the endometrium 
The endometrium is an active metabolic tissue which requires an adequate glucose supply for  
its proper function (Schulte et al., 2015). Insulin is regulating energy metabolism by 
stimulating glucose up-take in the cells (Diamanti-Kandarakis and Dunaif, 2012). Molecules 
that are required for insulin signaling, including IR, IRS, GLUT1, GLUT3 and GLUT4 are 
expressed in the human endometrium (Mioni et al., 2012;  Shang et al., 2012).  Their 
regulation has been proposed to be sex hormone dependent (Mioni et al., 2012). Women with 
PCOS often display insulin resistance which aggravates hyperandrogenic symptoms and 
features of this syndrome. These hormonal disturbances may affect the expression of 
molecules that are required for insulin-signaling in the endometrium and thereby its function. 
Several studies, including our own, have shown that lifestyle modification improves insulin 
sensitivity and ovulation rates (Moran et al., 2003;  Nybacka et al., 2011). However, the 
effect of lifestyle modification strategies on the expression of the molecules involved in 
insulin signaling in the human endometrium is largely unknown. We hypothesized, that an 
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individualized dietary and exercise program will promote a favorably effect on the systemic 
insulin sensitivity, as well as on insulin signaling in the endometrium. This is the first study to 
investigate the effect of dietary intervention and increased physical activity on endometrial 
insulin signaling in PCOS women.  
Clinical characteristics and endocrinological variables in OB-PCOS, OB-C, NW-PCOS and 
NW-C groups are presented in Table 5. Before intervention, OB-PCOS women had higher 
serum levels of total and free testosterone and lower FSH and SHBG as compared to the OB-
C group. 
Table 5. Clinical characteristics and endocrinological variables on cycle day 6-8 in overweight/ 
obese women with PCOS (OB-PCOS), obese controls (OB-C), normal weight PCOS (NW-
PCOS) and normal-weight controls (NW-C). 
 OB-PCOS# OB-C NW-PCOS NW-C 
 n =18  n = 10 n =11 n = 11 
Age 28.2 ± 4.9 33.5 ± 3.4 28.4 ± 5.5 27.2 ± 5.9 
BMI (kg/ m
2
) 37.4 ± 5.4 34.0 ± 5.1 21.9 ± 1.8 21.7 ± 1.8 
Endometrial thickness 
(mm) 
5.1 (3.7-7.5)
 a
 5.0 (4.2-6.5)
 a
 2.8 (2.1-4.7)
 b
 3.0 (2.4-3.9)
 b
 
Endocrinological 
variables 
    
LH (IU/I) 4.6 ± 1.6 
a
 4.9 ± 2.0 
ab
 8.6 ± 3.1 
b
 4.7 ± 1.1 
a
 
FSH (IU/I) 5.1 ± 1.1 
a
 7.3 ± 2.9 
b
 6.9 ± 2.1 
b
 6.7 ± 2.4 
b
 
Total testosterone (nmol/l) 1.3 ± 0.6 
a
 0.7 ± 0.2 
b
 1.2 ± 0.3 
ab
 1.0 ± 0.3 
ab
 
SHBG (nmol/l) 27.4 ± 11.3 
a
 41.9 ± 18.6 
b
 63.5 ± 25.7 
b
 68.4 ± 22.6 
b
 
Free testosterone (pmol/l) 30.8 ± 17.3 
a
 12.4 ± 5.1 
bc
 18.1 ± 5.5 
ab
 12.8 ± 3.7 
c
 
Estradiol (pmol/l) 148 ± 66 171 ± 70 108 ± 31 134 ± 70 
 
The values are presented as means ± SD or medians with quartile range (25
th
-75
th
 quartiles). 
#Prior to the intervention. 
Values with different letter designations (a, b, c) are significantly different (p<0.05). 
BMI, body mass index; FSH, follicle stimulating hormone; LH, luteinizing hormone; SHBG, sex biding  
globulin. 
Out of the 20 initially recruited overweight/obese women two dropped out for personal 
reasons and one was excluded from study III because the endometrial biopsy was too small, 
and all was used in study IV. Following three months of lifestyle intervention, 88% of OB-
PCOS women reduced their body weight by 5% on average. In 65% of the women, menstrual 
pattern was improved and in 35% ovulation was confirmed. Fasting insulin levels were 
significantly reduced and insulin sensitivity as measured by QUICKI, was enhanced. 
The endometrium from PCOS women and healthy BMI-matched controls was similar 
regarding expression of IR, on both mRNA and protein levels. Our findings are consistent 
with studies on other insulin-dependent tissues (fat and skeletal muscle), where the 
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expression of the IR in PCOS women did not differ from  healthy controls (Diamanti-
Kandarakis and Dunaif, 2012). Moreover, lifestyle intervention did not affect IR expression 
in the endometrium of overweight/obese women with PCOS. Impaired insulin sensitivity 
associated with this syndrome can be attributed to abnormalities of post-receptor signaling as 
has been proposed by several in vitro and in vivo studies (Dunaif et al., 2001;  Li et al., 2002;  
Diamanti-Kandarakis and Dunaif, 2012). 
Binding of insulin to the IR leads to its phosphorylation and activation of IRS1. The function 
of IRS1 can be determined by the levels of its activated (pY612IRS1) and inhibitory forms 
(pS312IRS1). We found that mRNA expression of IRS1 was lower in the combined (NW-
PCOS + OB-PCOS) group of PCOS women as compared to the healthy controls (NW-C + 
OB-C) (p<0.01) (Figure 23).  
          
Figure 23.  The left panel shows relative mRNA expression of the insulin receptor substrate 1 (IRS1) 
in proliferative endometrium of OB-PCOS women as compared to BMI matched controls. The right 
panel shows relative mRNA expression of IRS1 in proliferative endometrium of OB-PCOS women 
before and after lifestyle intervention.  
 
Following life-style intervention, mRNA expression of IRS1 increased in the endometrium of 
overweight/obese women with PCOS (Figure 23). Moreover, immunostaining of both 
activated and inhibitory forms of IRS1 were up-regulated by lifestyle intervention. 
Several glucose transporters have been found to be present in the human endometrium, 
among them GLUT4 which is located in intracellular vesicles. Insulin stimulation is required 
for its activation and translocation to the cell surface for glucose uptake. Lower mRNA and 
protein levels of GLUT4 have been found in the proliferative endometrium of 
hyperinsulinemic and obese PCOS women, while lean PCOS women displayed expression of 
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GLUT4 comparable to that seen in healthy controls (Mioni et al., 2004;  Mozzanega et al., 
2004;  Fornes et al., 2010). This finding is an agreement with the present study. We found 
lower GLUT4 mRNA expression in the overweight/obese PCOS women as compared to the 
BMI-matched controls. However, the expression of GLUT4 mRNA in lean PCOS women 
was comparable to the controls. The lower GLUT4 expression in the OB-PCOS women may 
be explained by the higher testosterone and insulin levels in this group. An in vitro study 
demonstrated that testosterone reduces expression of GLUT4 mRNA in endometrial 
glandular epithelial cells in culture (Zhang and Liao, 2010). Our lifestyle intervention had no 
major effect on GLUT4 expression. However, in the group of women with improved 
menstrual function, GLUT4 mRNA expression was higher, but did not reach significance 
(p=0.09). Thus, the effect of lifestyle intervention on the expression of GLUT4 in the 
endometrium of OB-PCOS is yet to be determined.  
GLUT1 is responsible for basal glucose uptake and was shown to be of importance for 
endometrial decidualization (Frolova and Moley, 2011). Little is known about its role in 
proliferative endometrium. In our study, expression of GLUT1 mRNA increased after 
lifestyle intervention in the OB-PCOS group (Figure 24). 
                               
Figure 24. Relative mRNA expression of the insulin glucose transporter 1 (GLUT1) in proliferative 
endometrium of OB-PCOS women before and after lifestyle intervention. 
Moreover, immunostaining of GLUT1 in the stromal compartment of the endometrium was 
also up-regulated by lifestyle intervention. Our findings may indicate that lifestyle 
intervention promotes a favorable effect on endometrial basal glucose up-take and thereby 
improves endometrial function. 
Lower expression of IRS1 and GLUT1 in overweight/obese PCOS suggests altered insulin 
signaling in the endometrium as compared to the healthy controls. To our knowledge, this is 
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the first study to demonstrate that lifestyle intervention up-regulates endometrial expression 
of molecules involved in insulin signaling in overweight/obese women with PCOS. We 
suggest that this treatment improves endometrial glucose homeostasis and thereby 
endometrial function in these women.  
4.2.2 Genomic and non-genomic estrogen signaling in the endometrium 
of PCOS women 
PCOS is associated with disturbances of sex hormone production. It is characterized by 
androgen excess and relatively low levels of progesterone due to anovulatory cycles (Giudice, 
2006;  Azziz et al., 2009). Endocrine and metabolic abnormalities that are present in PCOS 
may alter endometrial receptivity as revealed by implantation failure and increased incidence 
of endometrial hyperplasia and cancer in these women (Giudice, 2006;  Shang et al., 2012). 
An increased risk of endometrial hyperplasia can be attributed to the absence of the 
regulatory effects of progesterone on the endometrium (Giudice, 2006). Estrogens and their 
cognate receptors are important regulators of endometrial proliferation and differentiation 
(Giudice, 2006). However, little is known about their expression in the endometrium of 
PCOS women. In the present study, we investigated genomic and non-genomic estrogen 
receptors in the endometrium of PCOS women throughout the menstrual cycle and in relation 
to proliferation. 
We found that obese women with PCOS have decreased mRNA expression of ERα and 
ERα36, as well as a lower ERα/ERβ mRNA ratio in proliferative endometrium as compared 
to healthy BMI-matched controls (Figure 25). These findings are not in agreement with other 
studies. Vega and collaborators demonstrated higher immunostaining of ERα and ERβ in 
proliferative endometrium as compared to controls (Maliqueo et al., 2003;  Villavicencio et 
al., 2006). This discrepancy may be explained by the timing of biopsy collection and the BMI 
of the controls. In the above studies, biopsies were collected in anovulatory PCOS women but 
the duration of amenorrhea was not clear. Moreover, the controls were not BMI-matched. In 
our study, endometrial biopsies were collected on specific cycle days after spontaneous or 
induced menstruation and the controls were BMI-matched. 
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Figure 25. The left panel shows relative mRNA expression of the estrogen receptor α (ERα), β (ERβ), 
and their ratio in proliferative endometrium of OB-PCOS women as compared to BMI-matched 
controls. The right panel shows relative mRNA expression of the estrogen receptor α36 (ERα36) and 
G-protein coupled estrogen receptor-1(GPER) in proliferative endometrium of OB-PCOS women as 
compared to BMI-matched controls. 
 
In the combined group of PCOS women (OB-PCOS + NW-PCOS), the mRNA expression of 
ERα, ERα36 and the ERα/ERβ ratio was also lower as compared to the controls. The lower 
mRNA level of ERα and ERα36 in PCOS women correlated negatively with free testosterone 
(r= - 0.45, r= - 0.46 respectively). Testosterone administration in vitro was shown to promote 
an inhibitory effect on human endometrial proliferation (Rose et al., 1988). This effect of 
testosterone was proposed to be associated with the interaction between ER and AR pathways 
(Panet-Raymond et al., 2000). Moreover, testosterone administration was found to down-
regulate ER protein expression and reduce proliferation in vaginal tissue samples of young 
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women (Baldassarre et al., 2013). Thus, testosterone may interact via ER pathways in 
gynecological tissues.  
The ERα/ERβ mRNA ratio was also found to be lower in the combined group of 
overweight/obese women (OB-PCOS+OB-C) compared to the normal-weight women (NW-
PCOS+NW-C). However, in the overweight/obese women, the ratio was associated with a 
higher ERβ mRNA level and not with a lower ERα mRNA expression as in the PCOS 
women. Although, the particular mechanism behind the increased mRNA expression of ERβ 
in the endometrium of overweight/obese women is not known, our data suggest that 
proliferative endometrium of women with PCOS exhibits a lower ERα/ERβ ratio which can 
be even lower when obesity is present.   
Little information is available regarding ERα36 expression in the endometrium of PCOS 
women. In the present study, we observed a lower ERα36 mRNA expression in the 
endometrium of PCOS women compared with controls. This finding is in agreement with 
previous data where lower ERα36 mRNA expression in PCOS women was associated with 
endometrial hyperplasia (Lin et al., 2013). Thus, ERα36 expression in the proliferative 
endometrium of PCOS women is altered and needs further investigation. 
Following lifestyle intervention, the ERα/ERβ protein ratio increased in glandular epithelium 
and tended to increase in luminal epithelium in the proliferative endometrium of OB-PCOS 
women with improved menstrual function. A positive association between improved 
menstrual function and the ERα/ERβ protein ratio in stroma and glands in the endometrium 
was supported by correlation analyses (r= 0.55 and r= 0.75 respectively). A low ERα/ERβ 
ratio suggests relative over-expression and dominance of ERβ mediated effects in the 
endometrium of OB-PCOS women. Animal studies revealed that ERα is essential for PR up-
regulation (Critchley and Saunders, 2009). Altered expression of PRs was proposed to be 
associated with endometrial progesterone resistance and hyperplasia in PCOS patients (Li et 
al., 2014). Thus, increased endometrial ERα/ERβ ratio following lifestyle intervention 
indicates improvement in estrogen signaling and thereby in endometrial function. 
After lifestyle intervention, six women had restored ovulation and confirmed luteal phase 
while 12 remained anovulatory. Anovulatory women with PCOS had a higher expression of 
ERα mRNA on cycle day 21-23 as compared to controls. This finding is in agreement with a 
previous study where the ERα mRNA level was higher in midsecretory endometrium of 
PCOS women as compared to controls (Quezada et al., 2006). Furthermore, anovulatory 
women had a higher ERα/ERβ immunostaining ratio in glandular epithelium on cycle day 21-
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23. The same finding was observed in the study by Quezada et al., where higher ERα/ERβ 
ratio in midsecretory endometrium was suggested to show a predominance of ERα-mediated 
effects in this tissue (Quezada et al., 2006). Moreover, both mRNA and protein levels of 
GPER were higher on cycle day 21-23 in anovulatory women with PCOS compared to 
controls. The higher GPER levels can be related to the absence of the regulatory effect of 
progesterone in this group of women (Kolkova et al., 2010). An overexpression of GPER and 
higher ERα/ERβ ratio may further explain the higher proliferation activity, as revealed by 
Ki67 immunostaining in this group of women (Figure 26). Thus, our findings and previously 
published data support that anovulatory women with PCOS exhibit a higher proliferation 
activity and therefore the risk to develop endometrial abnormalities. Moreover, not only ERα 
but also GPER may play role in endometrial proliferative abnormalities observed in PCOS 
women. 
                          
Figure 26. Immunostaining of proliferation marker Ki67 in the endometrium of OB-PCOS women 
with confirmed luteal phase, OB-PCOS women with no luteal phase and BMI-matched controls. 
Significant changes between groups are marked with letters (p<0.05). 
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Women with PCOS and restored ovulation were showing intermediate levels of ER mRNAs 
as compared to the other groups, which were neither different from anovulatory OB-PCOS 
women nor controls. However, GPER immunostaining in stroma was higher in seceretory 
endometrium as compared to the controls and correlated positively with the proliferation 
marker Ki67 (r= 0.52). Thus, higher GPER expression might be associated with endometrial 
abnormalities in PCOS women. Since progesterone is a known opposing factor of estrogen 
activity in midsecretory endometrium, our findings make us to speculate about possible 
alterations in progesterone signaling in the endometrium of PCOS women. Several studies 
have raised the suggestion that women with PCOS exhibit a state of progesterone resistance, 
which is characterized by a decreased responsiveness of the target tissue to progesterone (Li 
et al., 2014). This is in agreement with our study where the rise in progesterone levels did not 
result in absolute suppression of proliferation activity.  
We have shown that PCOS women exhibit decreased endometrial expression of ERα, ERα36 
mRNA and ERα/ERβ ratio in the mid-follicular phase of the menstrual cycle that can 
aggravate in the presence of obesity. A low ERα/ERβ mRNA ratio in proliferative 
endometrium of PCOS women is associated with high testosterone levels, which may be the 
underlying mechanism for the impaired estrogen signaling in this tissue. Following life-style 
intervention the ERα/ERβ protein ratio was up-regulated in the group of OB-PCOS patients 
with improved menstrual function. We propose that up-regulation of the ERα/ERβ protein 
ratio in proliferative endometrium following lifestyle intervention improves estrogen 
signaling and thereby endometrial functioning in PCOS women. Furthermore, PCOS women 
with restored ovulation and confirmed luteal phase presented an ERα/ERβ mRNA and 
protein ratio in secretory endometrium comparable to that seen in the controls, while GPER 
expression was higher and correlated positively with the proliferative marker Ki67. It is likely 
that a high proliferation activity that is present in the secretory endometrium of PCOS women 
despite ovulation can be due to a non-genomic estrogen action via GPER.  
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5 A CRITICAL EVALUATION AND FUTURE PROSPECTS 
 
Our results concerning the effects of long-term sex hormone treatment on uterine expression 
and distribution of receptors involved in steroid hormone and thyroid signaling are based on 
experimental animal data. Despite obvious similarities in reproductive biology of non-human 
primates and humans, the endometrial regulation remains a complex process which could 
differ between species. A variety of factors including age, metabolism, lifestyle as well as 
individual sensitivity can modify hormone responsiveness of the endometrium, and therefore 
our findings should be interpreted with caution.  
A limitation with the monkey studies is the small number of subjects in each group and a 
limited amount of endometrial tissue. The same holds for the clinical studies. A larger sample 
size should minimize the risk of type II error. Furthermore, the follow-up after lifestyle 
intervention was limited to 3 months. A long-term follow-up period is needed to evaluate 
maintenance of both body weight and menstrual function. 
The endometrial biopsies obtained in the clinical studies were sufficient for RT-PCR and 
immunohistochemistry (IHC) analyses. Gene expression was evaluated in all cell types 
together (endometrium was homogenized), while in IHC different compartments of the 
endometrium were evaluated separately. IHC is a semi-quantitative method that allows 
investigating expression and distribution of the protein in the tissue of interest, while western 
blot could be used to quantify protein levels. Western blot would have been a good 
complimentary method in addition to those used in our studies but was not employed because 
of the insufficient amount of endometrial tissue.  
Our studies have raised several new questions regarding effects of sex steroid hormone 
disturbances, thyroid hormone dysfunction, insulin resistance and hyperinsulinemia on 
endometrial functioning. Further investigations are needed to clarify how these disorders can 
affect the endometrium. Increased knowledge about hormone signaling in the endometrium 
may in the long term contribute to better understanding and treatment of reproductive 
disorders.  
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6 CONCLUSIONS 
 
I. Long-term sex hormone treatment influences protein expression of steroid hormone 
receptors in monkey uterus. TIB treatment affects the expression of sex hormone 
receptors differently from that observed by conventional hormone treatment. 
Enhanced expression of AR by TIB may be of importance for endometrial atrophy 
and the beneficial bleeding profile associated with this treatment. 
II. All receptors involved in thyroid hormone function are expressed in the different 
compartments of the macaque uterus and are regulated by long-term sex hormone 
treatment. These findings raise the possibility of direct actions of TRH, TSH and 
thyroid hormones on endometrial function, which could be of clinical importance in 
women with thyroid dysfunction. 
III. Lifestyle intervention up-regulates endometrial mRNA and protein expression of 
molecules involved in insulin signaling in relation to improved menstrual function in 
overweight/obese women with PCOS. These findings provide evidence of in vivo 
regulation of insulin signaling in proliferative endometrium of women with PCOS.  
We propose that up-regulation of endometrial IRS1 and GLUT1 improves the glucose 
homeostasis and thereby restores the functioning of the endometrium in these women.  
IV. Estrogen receptor expression is altered in the endometrium of PCOS women. 
Lifestyle intervention changes genomic and non-genomic estrogen receptor levels 
towards normalization in proliferative and secretory endometrium of 
overweight/obese women with PCOS. Restored estrogen signaling may contribute to 
the improvement of endometrial functioning in these women. However, despite 
restored ovulation, the proliferative activity, as demonstrated by the proliferation 
marker Ki67, is higher in the secretory endometrium of the overweight/obese PCOS 
women. Elevated expression of GPER in the secretory endometrium may propose a 
mechanism behind high proliferation activity in PCOS women. 
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